Search clinical trials for: ZN-A-1041 MAD Capecitabine 1000 mg/m2 Trastuzumab 8 mg/kg iv. First Cycle
Total 8 results
-
Suzhou Zanrong Pharma LimitedRecruitingAdvanced Solid Tumors | HER2-positive Breast CancerChina
-
Suzhou Zanrong Pharma LimitedRecruitingAdvanced Solid Tumors | HER2-positive Breast CancerUnited States
-
The Netherlands Cancer InstituteRoche Pharma AG; Borstkanker Onderzoek GroepActive, not recruitingBreast Cancer | HER2 PositiveNetherlands
-
University of PittsburghGenentech, Inc.Completed
-
Vejle HospitalCompleted
-
Royal Marsden NHS Foundation TrustHoffmann-La Roche; Professor Cunningham's Clinical Research FundCompletedPancreatic CancerUnited Kingdom
-
Hellenic Oncology Research GroupTerminated
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States